Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Current influenza virus vaccines protect mostly against homologous virus strains; thus, regular immunization with updated vaccine formulations is necessary to guard against the virus' hallmark remodeling of regions that mediate neutralization. Development of a broadly protective influenza vaccine would mark a significant advance in human infectious diseases research. Antibodies with broad neutralizing activity (nAbs) against multiple influenza virus strains or subtypes have been reported to bind the stalk of the viral hemagglutinin, suggesting that a vaccine based on this region could elicit a broadly protective immune response. Here we describe a hemagglutinin subunit 2 protein (HA2)-based synthetic peptide vaccine that provides protection in mice against influenza viruses of the structurally divergent subtypes H3N2, H1N1, and H5N1. The immunogen is based on the binding site of the recently described nAb 12D1, which neutralizes H3 subtype viruses, demonstrates protective activity in vivo, and, in contrast to a majority of described nAbs, appears to bind to residues within a single α-helical portion of the HA2 protein. Our data further demonstrate that the specific design of our immunogen is integral in the induction of broadly active anti-hemagglutinin antibodies. These results provide proof of concept for an HA2-based influenza vaccine that could diminish the threat of pandemic influenza disease and generally reduce the significance of influenza viruses as human pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Towbin, H., Staehelin, T., & Gordon, J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4350 · Cited by 53,385
Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution
Wilson, I. A., Skehel, J. J., & Wiley, D. C. (1981) · Nature · doi:10.1038/289366a0 · Cited by 2,525
Self-citationAntibody Recognition of a Highly Conserved Influenza Virus Epitope
Ekiert, D. C., Bhabha, G., Elsliger, M.-A., Friesen, R. H. E., Jongeneelen, M., Throsby, M., Goudsmit, J., & Wilson, I. A. (2009) · Science · doi:10.1126/science.1171491 · Cited by 1,326 · cited 1×
“This division of the 16 subtypes correlates with two distinct basic structures taken by the stalk of the hemagglutinin, so that group 1 proteins have similar stalk structures, as do group 2 proteins (9).”
BackgroundSelf-citationSui, J., Hwang, W. C., Perez, S., Wei, G., Aird, D., Chen, L.-M., Santelli, E., Stec, B., Cadwell, G., Ali, M., et al. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1566 · Cited by 1,130
Throsby, M., van den Brink, E., Jongeneelen, M., Poon, L. L. M., Alard, P., Cornelissen, L., Bakker, A., Cox, F., van Deventer, E., Guan, Y., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003942 · Cited by 737
Strategies to improve plasma half life time of peptide and protein drugs
Werle, M., & Bernkop-Schnürch, A. (2006) · Amino Acids · doi:10.1007/s00726-005-0289-3 · Cited by 660
Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain
Steel, J., Lowen, A. C., Wang, T. T., Yondola, M., Gao, Q., Haye, K., García-Sastre, A., & Palese, P. (2010) · mBio · doi:10.1128/mbio.00018-10 · Cited by 533
Self-citationInduction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination
Wei, C.-J., Boyington, J. C., McTamney, P. M., Kong, W.-P., Pearce, M. B., Xu, L., Andersen, H., Rao, S., Tumpey, T. M., Yang, Z.-Y., et al. (2010) · Science · doi:10.1126/science.1192517 · Cited by 337
Chen, J., Skehel, J. J., & Wiley, D. C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.8967 · Cited by 295
Wang, T. T., Tan, G. S., Hai, R., Pica, N., Petersen, E., Moran, T. M., & Palese, P. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000796 · Cited by 278
Self-citationBasler, C. F., Reid, A. H., Dybing, J. K., Janczewski, T. A., Fanning, T. G., Zheng, H., Salvatore, M., Perdue, M. L., Swayne, D. E., García-Sastre, A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.031575198 · Cited by 277
Self-citationSteel, J., Lowen, A. C., Pena, L., Angel, M., Solórzano, A., Albrecht, R., Perez, D. R., García-Sastre, A., & Palese, P. (2009) · Journal of Virology · doi:10.1128/jvi.01920-08 · Cited by 258
Self-citationVitamin B 6 Is Required for Full Motility and Virulence in Helicobacter pylori
Grubman, A., Phillips, A., Thibonnier, M., Kaparakis-Liaskos, M., Johnson, C., Thiberge, J.-M., Radcliff, F. J., Ecobichon, C., Labigne, A., de Reuse, H., et al. (2010) · mBio · doi:10.1128/mbio.00112-10 · Cited by 216
Bommakanti, G., Citron, M. P., Hepler, R. W., Callahan, C., Heidecker, G. J., Najar, T. A., Lu, X., Joyce, J. G., Shiver, J. W., Casimiro, D. R., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007465107 · Cited by 214
Mechanism of action of licensed vaccine adjuvants
Tritto, E., Mosca, F., & De Gregorio, E. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.084 · Cited by 213
Development of Effective Vaccines against Pandemic Influenza
Subbarao, K., Murphy, B. R., & Fauci, A. S. (2006) · Immunity · doi:10.1016/j.immuni.2005.12.005 · Cited by 168
Khurana, S., Suguitan, A. L., Rivera, Y., Simmons, C. P., Lanzavecchia, A., Sallusto, F., Manischewitz, J., King, L. R., Subbarao, K., & Golding, H. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000049 · Cited by 168
HIV-1 and influenza antibodies: seeing antigens in new ways
Kwong, P. D., & Wilson, I. A. (2009) · Nature Immunology · doi:10.1038/ni.1746 · Cited by 127
Self-citationCutting Edge: Stealth Influenza Virus Replication Precedes the Initiation of Adaptive Immunity
Moltedo, B., López, C. B., Pazos, M. A., Becker, M. I., Hermesh, T., & Moran, T. M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900091 · Cited by 101
Self-citationAntiviral Instruction of Bone Marrow Leukocytes during Respiratory Viral Infections
Hermesh, T., Moltedo, B., Moran, T. M., & López, C. B. (2010) · Cell Host & Microbe · doi:10.1016/j.chom.2010.04.006 · Cited by 73
Self-citationEckert, D. M., & Kay, M. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008672107 · Cited by 7
Cited by
A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses
Ekiert, D. C., Friesen, R. H. E., Bhabha, G., Kwaks, T., Jongeneelen, M., Yu, W., Ophorst, C., Cox, F., Korse, H. J. W. M., Brandenburg, B., et al. (2011) · Science · doi:10.1126/science.1204839 · Cited by 822
Self-citationPeptide-Based Vaccines: Current Progress and Future Challenges
Malonis, R. J., Lai, J. R., & Vergnolle, O. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00472 · Cited by 602
Advances in the development of influenza virus vaccines
Krammer, F., & Palese, P. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4529 · Cited by 597
Self-citationBroadly Neutralizing Antiviral Antibodies
Corti, D., & Lanzavecchia, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095916 · Cited by 475
Krammer, F., Pica, N., Hai, R., Margine, I., & Palese, P. (2013) · Journal of Virology · doi:10.1128/jvi.00641-13 · Cited by 423
Self-citation
Metadata
- Authors
- Wang, T. T., Tan, G. S., Hai, R., Pica, N., Ngai, L., Ekiert, D. C., Wilson, I. A., García-Sastre, A., Moran, T. M., & Palese, P.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2010-10-18
- Volume
- 107
- Issue
- 44
- Pages
- 18979-18984
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2106088492
- Cited by
- 302
- References
- 21
- FWCI
- 24.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.